Compare JUBILANT LIFE SCIENCES with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs CADILA HEALTHCARE - Comparison Results

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES CADILA HEALTHCARE JUBILANT LIFE SCIENCES/
CADILA HEALTHCARE
 
P/E (TTM) x 12.3 29.4 41.9% View Chart
P/BV x 2.3 3.5 65.4% View Chart
Dividend Yield % 0.6 1.0 66.0%  

Financials

 JUBILANT LIFE SCIENCES   CADILA HEALTHCARE
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-19
CADILA HEALTHCARE
Mar-19
JUBILANT LIFE SCIENCES/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs898432 207.7%   
Low Rs618306 201.5%   
Sales per share (Unadj.) Rs572.0128.6 444.8%  
Earnings per share (Unadj.) Rs36.218.5 195.3%  
Cash flow per share (Unadj.) Rs59.524.4 244.0%  
Dividends per share (Unadj.) Rs4.503.50 128.6%  
Dividend yield (eoy) %0.60.9 62.7%  
Book value per share (Unadj.) Rs301.9101.5 297.6%  
Shares outstanding (eoy) m159.281,023.74 15.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.32.9 46.1%   
Avg P/E ratio x20.919.9 105.0%  
P/CF ratio (eoy) x12.715.1 84.1%  
Price / Book Value ratio x2.53.6 68.9%  
Dividend payout %12.418.9 65.8%   
Avg Mkt Cap Rs m120,694378,170 31.9%   
No. of employees `0002.412.4 19.2%   
Total wages/salary Rs m19,26021,241 90.7%   
Avg. sales/employee Rs Th38,120.610,585.0 360.1%   
Avg. wages/employee Rs Th8,058.41,707.8 471.9%   
Avg. net profit/employee Rs Th2,414.31,526.5 158.2%   
INCOME DATA
Net Sales Rs m91,108131,656 69.2%  
Other income Rs m3572,011 17.8%   
Total revenues Rs m91,466133,667 68.4%   
Gross profit Rs m17,39029,731 58.5%  
Depreciation Rs m3,7095,986 62.0%   
Interest Rs m2,1981,935 113.6%   
Profit before tax Rs m11,84023,821 49.7%   
Minority Interest Rs m0469 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-2,8020-   
Tax Rs m3,2685,303 61.6%   
Profit after tax Rs m5,77018,987 30.4%  
Gross profit margin %19.122.6 84.5%  
Effective tax rate %27.622.3 124.0%   
Net profit margin %6.314.4 43.9%  
BALANCE SHEET DATA
Current assets Rs m45,84884,981 54.0%   
Current liabilities Rs m20,89773,425 28.5%   
Net working cap to sales %27.48.8 312.0%  
Current ratio x2.21.2 189.6%  
Inventory Days Days5775 76.2%  
Debtors Days Days51110 46.5%  
Net fixed assets Rs m65,498133,493 49.1%   
Share capital Rs m1591,024 15.6%   
"Free" reserves Rs m47,930102,839 46.6%   
Net worth Rs m48,089103,863 46.3%   
Long term debt Rs m42,42939,497 107.4%   
Total assets Rs m114,685234,831 48.8%  
Interest coverage x6.413.3 48.0%   
Debt to equity ratio x0.90.4 232.0%  
Sales to assets ratio x0.80.6 141.7%   
Return on assets %6.98.9 78.0%  
Return on equity %12.018.3 65.6%  
Return on capital %12.418.3 67.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,42248,404 25.7%   
Fx outflow Rs m17,22711,593 148.6%   
Net fx Rs m-4,80536,811 -13.1%   
CASH FLOW
From Operations Rs m11,21528,823 38.9%  
From Investments Rs m-10,118-57,387 17.6%  
From Financial Activity Rs m6,57418,846 34.9%  
Net Cashflow Rs m7,612-7,105 -107.1%  

Share Holding

Indian Promoters % 45.6 74.8 61.0%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 8.3 104.8%  
FIIs % 21.2 5.9 359.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 11.0 191.8%  
Shareholders   23,815 44,069 54.0%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  WOCKHARDT  NOVARTIS  PANACEA BIOTECH  

Compare JUBILANT LIFE SCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slips Over 550 Points; Nifty Falls Below 10,700 Mark(11:30 am)

Share markets in India have extended early losses and are presently trading deep in the red.Benchmark indices edged lower today tracking weak Asian markets.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

These 3 Recent Events Will Impact the Price of Gold(Fast Profits Daily)

Jul 1, 2020

Recent developments in the bullion market may put some short term pressure on gold prices.

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Jul 14, 2020 12:07 PM

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES - NATCO PHARMA COMPARISON

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS